A Study of GFH009 in Combination with Zanubrutinib in Subjects with Relapsed or Refractory DLBCL
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Large B-cell Lymphoma
DRUG: GFH009|DRUG: Zanubrutinib|DRUG: GFH009|DRUG: Zanubrutinib
Phase Ib: adverse events(AEs), Incidence of DLT events, incidence and severity of AEs and serious adverse events (SAEs), Electrocardiogram changes, From Screening (Day -28 to Day-1) to 30 days ±7 days after the last dose, or until the start of a new anti-tumor therapy，assessed up to 32 months|Phase II: ORR, ORR(Objective Response Rate) as assessed by the investigator according to the 2014 Lugano standards, From Screening (Day -28 to Day-1) to 30 days ±7 days after the last dose,or until the start of a new anti-tumor therapy, assessed up to 32 months
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)